Fifth European International Kidney Cancer Symposium Agenda
7 May 2010
Molecular Classification, Ferran Algaba, M.D.
Partial Nephrectomy, Arnaud Méjean, M.D., Ph.D.
Non-ablative Techniques, Jan Roigas, M.D., Ph.D.
Banking Issues , Rosamonde E. Banks, Ph.D.
New Pathway for Metastatic RCC , Daniel Cho, M.D.
New Imaging Techniques in RCC , Per Sandström, M.D., Ph.D.
Access to Drugs: a NICE Point of View , Peter Clark, M.D.
Can We Predict Activity or Toxicity of Targeted Agents with SNPs? Ram Ganapathi, Ph.D.
Every Small Renal Mass Should be Biopsied, PRO - Michael Aitchison, M.D. CON - Ziya Kirkali, M.D.
Neoadjuvant Treatment is the Future for Poor Risk Patients, PRO – Brian I. Rini, M.D. CON – Christopher G. Wood, M.D., FACS
VEGF Inhibition is Enough Choice in mRCC, PRO – Manuela Schmidinger CON – Tim Eisen, M.D. |
8 May 2010
Mechanisms of Resistance to Targeted Agents , Michael B. Atkins, M.D.
Are RECIST Criteria Still Useful? PRO – Sergio Bracarda, M.D. CON – Paul Nathan, M.D.
Alternating VEGF and mTOR Pathways, PRO – Thomas Hutson, D.O., Pharm.D. CON – Joaquim Bellmunt, M.D.
Maintenance Therapy after CR, PRO –Camillo Porta, M.D. CON – Alain Ravaud, M.D., Ph.D.
Skin Toxicity , Caroline Robert, M.D.
Anorexia and Denutrition , Riccardo Caccialanza, M.D.
Hypertension , James Larkin, Ph.D., MRCP
Management of Surgical Complications , Axel Bex, M.D., Ph.D.
GI Toxicity , Fabio Calabró, M.D.
Pulmonary Toxicity , Philippe Camus, M.D.
Metabolic Syndromes , Cezary Szylick, M.D.
Small Tumors , Hendrik Van Poppel, M.D.
Slow Growing Metastatic RCC , Thomas E. Hutson, D.O., Pharm.D.
Poor Risk Patient , Didier Jacqmin, M.D.
Elderly Patients , Sylvie Négrier, M.D.
Case Presentations: Laurence Albiges, M.D ., Aurore Blésius, M.D ., Linda Cerbone, M.D.,
Ibrahim Cevik, M.D ., Rosalie Fisher , Sara Ramsey, M.D. , Sandra Waalkes, M.D. |
First European Kidney Cancer Nursing Conference Agenda
Epidemiology and Pathophysiology of Renal Cance r, Duncan Gilbert, M.A., MRCP, FRCR, Ph.D.
Management of the Primary Tumour , Amanda Baxter, R.N., B.Sc.
Systemic Care Session C , Susan Holmes , Lynda Pyle, S.R.N., B.Sc., Alison Stretch, S.R.N.
Systemic Care Session I, II, III (randomly ordered)
Systemic Care Session I, II, III
Systemic Care Session I, II, III
Systemic Care Session I, II, III
Systemic Care Session I, II, III
Patient Issues in Long Term Management of mRCC , Lynda Pyle, S.R.N., B.Sc.
Patient's View, Bruna Carnevale (no presentation available)
|
London Kidney Cancer Patient – Survivor Seminar Agenda
Kidney Cancer Overview: Incidence, Causes, and Risk Factors , Paul Nathan, M.D.
Surgery for Renal Cancer: What are the Options? Michael Aitchison, M.D.
Is Treatment after Surgery (Adjuvant) Needed After Surgery? Tim Eisen, M.D.
New Treatments for Advanced Renal Cancer: Sutent, Nexavar, Toricel, Everolimus, Bevacizumab + Interferon, James Larkin, Ph.D., MRCP
Is there a role for Interleukin-2? Robert Hawkins, Ph.D., FRCP
Vaccines for Renal Cancer: Any Information? Hardev Pandha, Ph.D., FRCP, FRACP
Future Directions in Renal Cancer Therapy , Bernard Escudier, M.D.
Symptom & Side Effect Management , Lynda Pyle, S.R.N., B.Sc.
Adjustment to the Diagnosis , Natalie Doyle, M.Sc., R.N.
How to Decide on Treatment , Lisa Pickering
Patient Appeals, Peter Telford
Patient Advocacy, Sarah H.W. Miller
|
| Click the title of any presentation to view the related file in PDF format |
|
|
We are a Charity Navigator 4-star Charity
